Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 9.9% – Should You Sell?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares traded down 9.9% during mid-day trading on Thursday . The stock traded as low as $12.86 and last traded at $12.8130. 778,966 shares changed hands during trading, a decline of 59% from the average session volume of 1,898,585 shares. The stock had previously closed at $14.22.

Analysts Set New Price Targets

Several analysts have weighed in on ADPT shares. BTIG Research boosted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Price Performance

The company has a market capitalization of $1.87 billion, a P/E ratio of -30.52 and a beta of 2.19. The stock’s 50 day moving average is $16.68 and its 200-day moving average is $15.87.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue for the quarter was up 51.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.23) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, insider Harlan S. Robins sold 14,233 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $16.52, for a total transaction of $235,129.16. Following the completion of the transaction, the insider directly owned 1,155,291 shares in the company, valued at $19,085,407.32. This trade represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $15.09, for a total value of $574,536.66. Following the completion of the transaction, the insider directly owned 321,967 shares of the company’s stock, valued at approximately $4,858,482.03. This represents a 10.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 1,209,806 shares of company stock worth $19,656,239. 6.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ADPT. Ameriprise Financial Inc. grew its holdings in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies during the 4th quarter valued at $65,942,000. Geode Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after purchasing an additional 102,362 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.